Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 25, Pages 6535-6543
Publisher
American Society of Hematology
Online
2011-10-13
DOI
10.1182/blood-2011-05-354530
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
- (2011) G. Avvisati et al. BLOOD
- Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia
- (2011) Ardeshir Ghavamzadeh et al. JOURNAL OF CLINICAL ONCOLOGY
- Modern Approaches to Treating Acute Promyelocytic Leukemia
- (2011) Miguel A. Sanz et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
- (2010) M. A. Sanz et al. BLOOD
- Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia
- (2010) J. Imagawa et al. BLOOD
- Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
- (2010) F. Lo-Coco et al. BLOOD
- Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
- (2010) B. L. Powell et al. BLOOD
- Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
- (2010) P. Montesinos et al. BLOOD
- Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia
- (2010) Steven D. Gore et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemotherapy
- (2010) Pau Montesinos et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data
- (2010) Vikram Mathews et al. JOURNAL OF CLINICAL ONCOLOGY
- How I treat acute promyelocytic leukemia
- (2009) M. S. Tallman et al. BLOOD
- Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience
- (2009) Charikleia Kelaidi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
- (2009) David Grimwade et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
- (2008) M. A. Sanz et al. BLOOD
- Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
- (2008) M. A. Sanz et al. BLOOD
- Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
- (2008) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started